Edmond joined Imperial in February 2022 as an Industry Partnerships and Commercialisation Executive. He primarily takes care of IP and licensing cases from the Faculty of Natural Sciences. Prior to joining Imperial, Edmond worked in Royal College of Art as...
Dr Amritha Nair is an Industry Partnerships and Commercialisation Senior Executive in the Faculty of Medicine at Imperial College London. Amritha works across the entire innovation lifecycle from assessment, protection, and management of Intellectual property;...
A novel gene therapy for Huntington’s Disease that leverage zinc finger protein technology.
Imperial.Tech.Pitch: Affordable technologies for an ageing society centred on the premise that within 20 years, there will be 25% fewer taxpayers to pensioners in the UK than in 2020.
Small molecule inhibitors with potential for use in the treatment of neurodegenerative diseases such as Huntington’s disease, viral conditions such as HIV, and cancers
A fully flexible, scalable and low-cost detection platform to sense multiple protein targets simultaneously by grafting specific sequences along the backbone of a double-stranded DNA carrier.
Learn about our programme of events and sign up to be alerted for future events
A zinc finger to target both the ALS and FTD therapeutically
A zinc finger (zf) to target the FXTAS mutation therapeutically
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.